Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

@article{Kim2008GefitinibVD,
  title={Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.},
  author={Edward S. Kim and Vera Hirsh and Tony Shu Kam Mok and Mark A. Socinski and Radj Gervais and Yi-Long Wu and Long-Yun Li and Claire L Watkins and Mark V Sellers and Elizabeth S. Lowe and Yan Sun and Mei-lin Liao and Kell Osterlind and Martin Reck and Alison A Armour and Frances A. Shepherd and Scott Michael Lippman and Jean-yves Douillard},
  journal={Lancet},
  year={2008},
  volume={372 9652},
  pages={1809-18}
}
BACKGROUND Two phase II trials in patients with previously-treated advanced non-small-cell lung cancer suggested that gefitinib was efficacious and less toxic than was chemotherapy. We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy. METHODS We undertook an open-label phase III study with recruitment between March 1, 2004, and Feb 17, 2006, at 149 centres in 24 countries. 1466… CONTINUE READING
Highly Influential
This paper has highly influenced 40 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS